Joshua Zeidner
UNC Lineberger Comprehensive Cancer Center · University of North Carolina, Chapel Hill
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joshua Zeidner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07605949 · Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLUNC Lineberger Comprehensive Cancer Center · not yet recruiting · Leukemia Acute Myeloid · principal investigator
- Ph2NCT05442216 · Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsJoshua Zeidner · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT04872478 · Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALMeryx, Inc. · recruiting · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:41 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.J Clin Oncol · 2023182 citationsRCR 15.3
- 177 citationsRCR 5.7
- 135 citationsRCR 10.8
- Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.Leukemia · 202198 citationsRCR 5.4
- A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.Clin Cancer Res · 201885 citationsRCR 2.6
- Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.Blood Cancer Discov · 202184 citationsRCR 4.1
- 82 citationsRCR 2.5
- 71 citationsRCR 16.3
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.J Clin Oncol · 202558 citationsRCR 13.6
- A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.Haematologica · 201443 citationsRCR 1.5